Recce Pharmaceuticals (ASX:RCE) completed the dosing of 30 patients for a phase two trial investigating the use of the Recce 327 topical gel in patients with acute bacterial skin and skin structure infections, according to a Tuesday filing with the Australian bourse.
The open-label study aims to assess the safety and tolerability, plasma pharmacokinetics, and efficacy of the topical gel following daily application for seven to 14 days, the filing said.
Results from the study are anticipated within the first quarter, per the filing.
Shares of the pharmaceutical firm rose past 2% in recent Tuesday trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。